Reuters logo
MARKET EYE-Credit Suisse upgrades Dr Reddy's on US outlook
December 13, 2012 / 3:47 AM / in 5 years

MARKET EYE-Credit Suisse upgrades Dr Reddy's on US outlook

* Credit Suisse upgrades Dr. Reddy's Laboratories to
'outperform' from 'neutral' and raises its target price to 2,150
rupees from 1,900 rupees, citing expectations for a strong pick
up in U.S. sales in the coming quarters.
* Credit Suisse also notes the market share for Dr. Reddy's
Metoprolol drug, used for hypertension, is increasing.
* Dr. Reddy's also expects upcoming approval of two limited
competition products in the United States, Credit Suisse says
after meeting with the drug maker's management.
* Dr. Reddy's also expects fiscal 2015 growth in the United
States to be stronger than fiscal 2014 due to some "significant"
launches.

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below